CPHI
China Pharma Holdings Inc
AMEX · Pharmaceuticals
$0.69
+0.06 (+10.14%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.76M | 1.71M | 1.69M |
| Net Income | 211.5K | 218.9K | 263.0K |
| EPS | — | — | — |
| Profit Margin | 12.0% | 12.8% | 15.6% |
| Rev Growth | +14.9% | -8.6% | -6.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.42M | 1.64M | 1.66M |
| Total Equity | 2.96M | 2.45M | 2.52M |
| D/E Ratio | 0.48 | 0.67 | 0.66 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 367.9K | 383.8K | 387.9K |
| Free Cash Flow | 192.2K | 127.8K | 154.0K |